Adverum Biotechnologies, Inc. (NASDAQ:ADVM) is scheduled to issue its quarterly earnings data on Monday, August 7th. Analysts expect the company to announce earnings of ($0.33) per share for the quarter.
Adverum Biotechnologies (NASDAQ:ADVM) last posted its quarterly earnings data on Tuesday, May 9th. The biotechnology company reported ($0.38) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by $0.12. The firm had revenue of $0.46 million for the quarter. Adverum Biotechnologies had a negative net margin of 6,928.21% and a negative return on equity of 24.04%. On average, analysts expect Adverum Biotechnologies to post $-1.50 EPS for the current fiscal year and $-1.45 EPS for the next fiscal year.
Shares of Adverum Biotechnologies, Inc. (ADVM) opened at 2.50 on Friday. The company’s market capitalization is $107.17 million. The firm’s 50-day moving average price is $2.64 and its 200 day moving average price is $2.74. Adverum Biotechnologies, Inc. has a 52-week low of $2.45 and a 52-week high of $4.86.
ILLEGAL ACTIVITY NOTICE: “Adverum Biotechnologies, Inc. (NASDAQ:ADVM) to Release Quarterly Earnings on Monday” was published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://stocknewstimes.com/2017/08/06/adverum-biotechnologies-inc-nasdaqadvm-to-release-quarterly-earnings-on-monday.html.
A number of research firms recently weighed in on ADVM. Zacks Investment Research raised shares of Adverum Biotechnologies from a “sell” rating to a “hold” rating in a research report on Monday, July 17th. ValuEngine lowered shares of Adverum Biotechnologies from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd.
Adverum Biotechnologies Company Profile
Adverum Biotechnologies, Inc, formerly Avalanche Biotechnologies, Inc, is a gene therapy company. The Company is engaged in discovering and developing medicines to patients suffering from chronic or debilitating disease. The Company operates and manages its business in the segment of developing and commercializing gene therapeutics.
Receive News & Ratings for Adverum Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adverum Biotechnologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
